Xcout IntelAprea Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Aprea Therapeutics, Inc. among biotech companies — ranked by similarity to what Aprea Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Aprea Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Aprea Therapeutics, Inc. at a glance
Aprea Therapeutics, Inc. is a biotech company headquartered in Boston, United States. It is publicly listed (APRE) with a market capitalisation of $7.5M. Xcout tracks 32 named people at Aprea Therapeutics, Inc., including Oren Gilad, Ph.D. (President and CEO).
Aprea Therapeutics, Inc. leadership
- Oren Gilad, Ph.D.President and CEO
- John HamillSenior Vice President, Chief Financial Officer, Principal Accounting Officer & Secretary
- Eugene KennedyChief Medical Advisor
- Lars AbrahmsenSenior Vice President & Chief Scientific Officer
- Zeev WeissChief Business Advisor
- Oren GiladCo-Founder, Chief Executive Officer, President and Director
26 more named people on record for Aprea Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Aprea Therapeutics, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $5.7M | 8 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Aprea Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Aprea Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Biotechnology
Artios Pharma is an independent biotechnology company headquartered at the Babraham Research Campus in Cambridge, United Kingdom, focused on discovering novel cancer therapies through DNA damage response mechanisms.
Biotechnology
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Biotechnology
Accent Therapeutics, Inc. is a biopharmaceutical company headquartered in Lexington, Massachusetts, focused on translating scientific research into novel therapeutics. The company conducts clinical trials, such as Phase 1/2 studies, targeting oncology and other serious diseases.
Biotechnology
Auron Therapeutics, Inc. is a biotechnology company headquartered in Newton, Massachusetts. The company focuses on targeting cell states to deliver next-generation targeted cancer therapies.
Similar biotech company
Pretzel Therapeutics is a biotechnology company headquartered in Boston, Massachusetts, advancing a new class of medicines that target cellular energetics and mitochondrial function.
Biotechnology
Ayala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Monmouth Junction, New Jersey. The company focuses on developing targeted therapeutics for rare tumors and aggressive cancers. It engages in clinical research and asset management within the biotechnology and pharmaceutical sector.
Similar biotech company
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
Biotechnology
Apexian Pharmaceuticals, Inc. is a clinical-stage research company based in Indianapolis, Indiana, dedicated to developing novel targeted therapeutics for oncology.
Biotechnology
Apmonia Therapeutics is a biotechnology company headquartered in Reims, France, committed to developing innovative therapeutic strategies for multiple types of cancer. Operating from its headquarters on Esplanade Roland, the firm advances oncology-focused drug candidates to target tumor progression. It is an active participant in the French biotech and life sciences ecosystem.
Similar biotech company
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Similar biotech company
Ratio Therapeutics is a clinical-stage pharmaceutical company headquartered in Boston, Massachusetts. The company employs a suite of innovative technologies for the discovery and early clinical development of targeted radiopharmaceuticals.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Aprea Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Aprea Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →